Centro De Inmunologia Molecular

Centro De Ingenieria Genetica Y Biotechnologia

Centro De Immunologia Molecular

Tania Carmenate Portilla

Kalet León Monzón

Agustin Bienvenido Lage Davila

Saumel Perez Rodriguez

Gerardo Enrique Guillen Nieto

Enrique Iglesias Perez

Gertrudis Rojas Dorantes

Maria De Jesus Leal Angulo

Eduardo Penton Arias

Dagmara Pichardo Diaz

Antonieta Herrera Buch

Verena Lucila Muzio Gonzalez

Julio Cesar Aguilar Rubido

Agustin Bienvenido Lage Dávila

Karina García Martínez

Saumel Pérez Rodríguez

Neris Michel Enamorado Escalona

Agustín Bienvenido Lage Dávila

Kalet Leon Monzon

Gloria Veliz Rios

Cirse Mesa Pardillo

Samuel Pérez Rodríguez

Maylin Diaz Martinez

Luis Javier Cruz Ricondo

Augustín Bienvendo Lage Davila

Maydel Hechavarria Gay

Diamile González Roche

Juan Joel Madrazo Pi&ntilde;ol

Ángel De Jesús Corria Osorio

Saumel Pérez Rodriguez

Amaury Pupo Meriño

Gabriel Márquez Perera

Kalet LEÓN MONZÓN

Amaury Pupo MERIÑO

Saumel PÉREZ RODRÍGUEZ

ÁNgel De Jesús Corria Osorio

Gabriel MÁRQUEZ Perera

Karina GARCÍA MATÍNEZ

Saumel PÉREZ Rodriguez

Agustín Bienvenido Lage Davila

Karina Garcia Martinez

Diamile Gonzalez Roche

Gabriel Marquez Perera

Amaury Pupo Merino

Angel De Corria Osorio

The present invention relates to the field of Biotechnology, particularly to a method based on the introduction of a single mutation in the genes encoding the human IL-2 and the muteins derived thereof that results in increased secretion levels in different hosts without affecting their biological functions. In particular, these mutations are based on a non-conservative change in the amino acid located in position 35 in the primary sequence of human IL-2, preferably the substitutions are K35E, K35D and K35Q. Another object of the present invention are the expression systems used to obtain both the recombinant human IL-2 and the muteins derived thereof using the method described in this invention. The above-mentioned method is useful to improve the production efficiency of the recombinant human IL-2 and the muteins derived thereof both at laboratory and industrial scales. The proteins obtained using this method can be used for therapeutic purposes as well as in the in vitro expansion of T cells for adoptive transfer therapies.

Method for increasing the secretion levels of interleukin 2 and muteins thereof by introducing a point mutation

The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGF&#x3b2; molecule whose primary sequence has a high homology with the sequence of human TGF&#x3b2;. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (T&#x3b2;RII and T&#x3b2;RIII). They have the property of antagonizing the signaling of all natural variants of TGF&#x3b2; ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.

TGF&#x3b2;-derived polypeptides and uses thereof

The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.

IL-2 derivative polypeptides

The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.

Immunomodulatory interleukin-2 polypeptides and methods of treating melanoma

The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.

Immunopotentiating formulations for vaccinal use

Growing community of inventors

Havana, Cuba

Tania Carmenate Portilla